Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

NCT05915351 PHASE2 ACTIVE_NOT_RECRUITING

A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

Details

Lead sponsor	University of Kansas Medical Center
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	28
Start date	Fri Jun 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pancreatic Ductal Adenocarcinoma
• Pancreas Adenocarcinoma
• Pancreas Cancer

Interventions

• Enfortumab vedotin

Countries

United States